Current Report Filing (8-k)
June 02 2020 - 5:26PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT
REPORT
PURSUANT
TO SECTION 13 OR 15(d) OF THE
SECURITIES
EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported):
May 27, 2020
Onconova Therapeutics, Inc.
(Exact name of Registrant as specified in
its charter)
Delaware
|
|
001-36020
|
|
22-3627252
|
(State or Other Jurisdiction
of Incorporation or Organization)
|
|
(Commission
File Number)
|
|
(I.R.S. Employer
Identification No.)
|
375 Pheasant Run
Newtown, PA 18940
(267) 759-3680
(Address, Including Zip Code, and Telephone
Number, Including Area Code, of Registrant’s Principal Executive
Offices)
Not Applicable
(Former name or former address, if changed
since last report)
Check the appropriate box below if the Form 8-K filing
is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨ Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨ Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17CFR 240.14a-12)
¨ Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨ Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of
the Act:
Title of each class
|
|
Trading Symbol(s)
|
|
Name of each exchange on which registered
|
Common Stock, par value $.01 per share
|
|
ONTX
|
|
The Nasdaq Stock Market LLC
|
Common Stock Warrants
|
|
ONTXW
|
|
The Nasdaq Stock Market LLC
|
Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of
the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ¨
Item 5.07. Submission of Matters to a Vote of Security Holders.
On May 27, 2020, Onconova Therapeutics, Inc. (the “Company”)
held its 2020 Annual Meeting of Stockholders (the “Annual Meeting”). At the Annual Meeting, the Company’s stockholders
voted on the following proposals:
Proposal 1. To elect the eight nominees named in the Company’s
proxy statement to serve for one-year terms as directors of the Company, with such terms expiring as of the Company’s 2021
Annual Meeting of Stockholders and, in each case, until a successor is elected and qualified. Each nominee for director was elected
by a vote of the stockholders as follows:
Name
|
|
For
|
|
|
Withheld
|
|
|
Broker Non-Votes
|
|
Steven M. Fruchtman
|
|
|
34,372,553
|
|
|
|
7,655,834
|
|
|
|
63,046,927
|
|
Jerome E. Groopman
|
|
|
35,358,898
|
|
|
|
6,669,489
|
|
|
|
63,046,927
|
|
Michael B. Hoffman
|
|
|
36,390,556
|
|
|
|
5,637,831
|
|
|
|
63,046,927
|
|
James J. Marino
|
|
|
35,456,525
|
|
|
|
6,571,862
|
|
|
|
63,046,927
|
|
Viren Mehta
|
|
|
35,561,850
|
|
|
|
6,466,537
|
|
|
|
63,046,927
|
|
E. Premkumar Reddy
|
|
|
36,275,353
|
|
|
|
5,753,034
|
|
|
|
63,046,927
|
|
Terri Shoemaker
|
|
|
35,991,681
|
|
|
|
6,036,706
|
|
|
|
63,046,927
|
|
Jack E. Stover
|
|
|
34,946,218
|
|
|
|
7,082,169
|
|
|
|
63,046,927
|
|
Proposal 3. To consider and vote upon an amendment and restatement
of the 2018 Omnibus Incentive Compensation Plan, as amended and restated, to increase the number of shares available under the
plan and to make certain other changes. The proposal was not approved by a vote of the stockholders as follows:
For
|
|
Against
|
|
Abstain
|
|
Broker Non-Votes
|
18,491,944
|
|
18,531,672
|
|
5,004,771
|
|
63,046,927
|
The final vote result for Proposal 3 differs from the preliminary
vote result for Proposal 3 announced at the Annual Meeting because certain votes were cast but not tabulated at the closing of
the polls for Proposal 3.
Proposal 4. To approve, on an advisory basis, the compensation
of our named executive officers. The proposal was approved by a vote of the stockholders as follows:
For
|
|
Against
|
|
Abstain
|
|
Broker Non-Votes
|
19,494,712
|
|
18,719,553
|
|
3,814,122
|
|
63,046,927
|
Proposal 5. To ratify the selection of Ernst & Young
LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2020. The
proposal was approved by a vote of the stockholders as follows:
For
|
|
Against
|
|
Abstain
|
|
Broker Non-Votes
|
89,588,775
|
|
9,298,258
|
|
6,188,281
|
|
None
|
Proposal 6. To consider and vote upon a proposal to adjourn
the Annual Meeting, if necessary, to solicit additional proxies in the event that there are not sufficient votes at the time of
the Annual Meeting to approve the reverse stock split. The proposal was approved by a vote of the stockholders as follows:
For
|
|
Against
|
|
Abstain
|
|
Broker Non-Votes
|
54,922,674
|
|
45,499,776
|
|
4,652,864
|
|
None
|
With regard to Proposal 4, the Company’s Compensation
Committee of the Board of Directors takes note of the results of the advisory “say-on-pay” proposal and expects to
consider these results and feedback from stockholder engagement among the factors considered in connection with continuing to discharge
its responsibilities in setting the compensation of the Company’s named executive officers.
Item 8.01 Other Events.
With respect to Proposal 2 to consider and vote upon an amendment
to the Company’s Tenth Amended and Restated Certificate of Incorporation, as amended, to combine outstanding shares of the
Company’s common stock into a lesser number of outstanding shares, or a “reverse stock split”, by a ratio of
not less than one-for-five and not more than one-for-twenty-five, with the exact ratio to be set within this range by the Company’s
Board of Directors in its sole discretion, in accordance with Proposal 6 which was approved by the stockholders, the Annual Meeting
was adjourned to June 26, 2020, at 10:30 a.m. Eastern Daylight Time.
The adjourned Annual Meeting will be held at the same virtual
meeting location, www.virtualshareholdermeeting.com/ONTX2020. This will enable the Company’s stockholders of record as of
the record date, which was March 30, 2020, additional time to consider and vote on Proposal 2, and enable the Company’s proxy
solicitor, MacKenzie Partners, Inc., more time to assist the Company with the solicitation of stockholder votes on Proposal 2.
At the adjourned Annual Meeting on June 26, 2020, stockholders
will be deemed to be present in person and vote at such adjourned meeting in the same manner as disclosed in the definitive proxy
statement the Company filed with the Securities and Exchange Commission on April 23, 2020 and mailed to the stockholders. Valid
proxies submitted prior to the reconvened Annual Meeting will continue to be valid for the upcoming reconvened Annual Meeting,
unless properly changed or revoked prior to votes being taken at such reconvened Annual Meeting.
The Company's Board of Directors expects to communicate with stockholders in the near future in connection with the adjourned
Annual Meeting.
SIGNATURE
Pursuant to the requirements of the Securities
Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
Dated: June 2, 2020
|
Onconova Therapeutics, Inc.
|
|
|
|
By:
|
/s/ MARK GUERIN
|
|
|
Name: Mark Guerin
|
|
|
Title: Chief Financial Officer
|
Onconova Therapeutics (NASDAQ:ONTX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Onconova Therapeutics (NASDAQ:ONTX)
Historical Stock Chart
From Apr 2023 to Apr 2024